読み込み中
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
前日終値
$23.53
+$0.71 · +3.11%
日中の時刻はETです。市場データは遅延する場合があります。
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
日中レンジ
現在 $23.53
52週レンジ
現在 $23.53
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
78
割安
センチメント
70
強気
リスク
60
やや高いリスク
モメンタム
43
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
日中レンジ
現在 $23.53
52週レンジ
現在 $23.53
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 7230.3万 USD | 2852万 USD | 716.3万 USD | — | 625.4万 USD |
| 売上原価 | 12.9万 USD | 5593.3万 USD | 4890万 USD | 6908万 USD | — |
| 粗利益 | 7217.4万 USD | −2741.3万 USD | −4173.7万 USD | −6908万 USD | 625.4万 USD |
| 研究開発 | 6481.3万 USD | 5593.3万 USD | 4890万 USD | 6998万 USD | 6852.4万 USD |
| 販売・一般管理 | 1960.8万 USD | 1800.7万 USD | 2290.9万 USD | 2393.4万 USD | 2878万 USD |
| 営業費用 | 8442.1万 USD | 1800.7万 USD | 2290.9万 USD | 2503.4万 USD | 1.39億 USD |
| 受取利息 | 599.6万 USD | 557.3万 USD | 345.1万 USD | 102.2万 USD | 30.2万 USD |
| 減価償却費と償却費 | 12.9万 USD | 12.9万 USD | 45万 USD | 49.8万 USD | 46.6万 USD |
| 営業利益 | −1211.8万 USD | −4542万 USD | −6464.6万 USD | −9411.4万 USD | −1.33億 USD |
| 純利益 | −612.2万 USD | −4017.7万 USD | −6122.8万 USD | −9309.2万 USD | −1.3億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$51.67
上昇余地（119.59%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1389.87万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM790.49万0.01%787.4億 USD0.19%$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI697.86万0.07%98.74億 USD0.35%$153.77+3.00%
Vanguard Extended Market ETFVXF443.53万0.00%954億 USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO190.15万0.01%180億 USD0.06%$112.66+0.50%
Vanguard Health Care ETFVHT112.38万0.01%220億 USD0.09%$319.01+1.64%
iShares Micro-Cap ETFIWC96.73万0.07%13.17億 USD0.60%$183+0.11%
Fidelity Enhanced Small Cap ETFFESM52.02万0.01%64.1億 USD0.28%$45.46+0.46%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOVanguard Health Care ETFVHTiShares Micro-Cap ETFIWCFidelity Enhanced Small Cap ETFFESMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
